Showing 31 - 40 of 801
The US Food and drug Administration (FDA) is estimated to regulate markets accounting for about 20% of consumer spending in the US. This paper proposes a general methodology to evaluate FDA policies, in general, and the central speed-safety tradeoff it faces, in particular. We apply this...
Persistent link: https://www.econbiz.de/10005580068
Persistent link: https://www.econbiz.de/10007984385
Persistent link: https://www.econbiz.de/10008886614
The U.S. Food and Drug Administration (FDA) is estimated to regulate markets accounting for about 20% of consumer spending in the U.S. Despite the FDA's strict adherence to evidence-based evaluation of the safety and efficacy of the products it regulates, there exists no generally agreed upon...
Persistent link: https://www.econbiz.de/10005108843
Persistent link: https://www.econbiz.de/10003543701
Persistent link: https://www.econbiz.de/10006957262
Persistent link: https://www.econbiz.de/10003663158
In the United States, the safety and efficacy of medical devices are regulated by the US Food and Drug Administration (FDA), which must successfully navigate a crucial tradeoff between speed and safety in approving applications for new devices. Although a shorter (and potentially less thorough)...
Persistent link: https://www.econbiz.de/10012852137
In the United States, drug safety and efficacy are primarily regulated by the Food and Drug Administration (FDA) and the legal system, which gives manufacturers large incentives to produce safe drugs and provide proper warnings for side effects, since patients can sue manufacturers that provide...
Persistent link: https://www.econbiz.de/10005084722
Perhaps the most important change of the last century was the great expansion of life itself -- in the US alone, life expectancy increased from 48 to 78 years. Recent economic estimates confirm this claim, finding that the economic value of the gain in longevity was on par with the value of...
Persistent link: https://www.econbiz.de/10005720142